Document Detail

Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin.
MedLine Citation:
PMID:  18974646     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Des-gamma-carboxy prothrombin (DCP) is a serum protein produced by hepatocellular carcinoma (HCC) cells in the absence of vitamin K. Serum and tissue DCP expressions are thought to reflect the biological malignant potential of HCC. Hence, we aimed to examine the efficacy of vitamin K(2) on the production of DCP as well as tumor cell growth and invasion. METHODS: Cell growth and viability were evaluated by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. The in vivo efficacy of vitamin K(2) was examined in nude mice bearing HCC cells. A 24-well transwell chamber was used to evaluate the motility and invasive ability of HCC cells. Levels of DCP in supernatant of cultures and in serum of mice were measured using an electrochemiluminescence immunoassay method. Western blot and immunohistochemical analysis were employed to evaluate the expression of DCP in HCC. RESULTS: Vitamin K(2) (2-40 muM) significantly decreased the levels of DCP production in supernatant of PLC/PRF/5 and HepG2 cells and in serum of nude mice bearing HCC xenografts. The inhibition of DCP was also observed using the assays of Western blot analysis in HCC cultures and immunohistochemical analysis in HCC xenografts in mice. As a result of administration of vitamin K(2), the capacity of HCC growth was inhibited and the invasion and migration of tumor cells were decreased. Furthermore, the inhibitory effects of HCC growth were also observed in vivo and the sensitivity was well correlated with the decrease of DCP in the serum of mice. CONCLUSION: Vitamin K(2) might suppress the growth and invasion of HCC cells via decrease of DCP.
Meng Ma; Xian-Jun Qu; Guo-Ying Mu; Ming-Hui Chen; Yan-Na Cheng; Norihiro Kokudo; Wei Tang; Shu-Xiang Cui
Related Documents :
918566 - Stem cells and small lymphocytes of congenitally asplenic-athymic mice. quantitative an...
1317746 - Cytotoxic analog of somatostatin containing methotrexate inhibits growth of mia paca-2 ...
2303296 - Estrogen- and androgen-responsive growth of human ovarian adenocarcinoma heterotranspla...
21419086 - Anticancer potentials of root extract of polygala senega against benzo[a]pyrene-induced...
3702326 - An improved procedure for obtaining germ-free laboratory mice.
20591496 - Developmental ontogeny of autoantigens associated with localized autoimmunity in murine...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-10-31
Journal Detail:
Title:  Chemotherapy     Volume:  55     ISSN:  1421-9794     ISO Abbreviation:  Chemotherapy     Publication Date:  2009  
Date Detail:
Created Date:  2008-12-18     Completed Date:  2009-02-11     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0144731     Medline TA:  Chemotherapy     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  28-35     Citation Subset:  IM    
Copyright Information:
(c) 2008 S. Karger AG, Basel.
Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / metabolism*
Blotting, Western
Carcinoma, Hepatocellular / metabolism*,  pathology
Cell Division / drug effects
Cell Line, Tumor
Chemiluminescent Measurements
Liver Neoplasms / metabolism*,  pathology
Mice, Nude
Neoplasm Invasiveness
Protein Precursors / drug effects,  metabolism*
Prothrombin / drug effects,  metabolism*
Vitamin K 2 / metabolism,  pharmacology*
Reg. No./Substance:
0/Biological Markers; 0/Protein Precursors; 11032-49-8/Vitamin K 2; 53230-14-1/acarboxyprothrombin; 9001-26-7/Prothrombin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clin...
Next Document:  Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria.